Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Nuvectis Pharma in a research note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2028 earnings at $3.61 EPS.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same quarter last year, the business posted ($0.37) EPS.
Separately, HC Wainwright reiterated a "buy" rating and set a $21.00 price target on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.
View Our Latest Analysis on Nuvectis Pharma
Nuvectis Pharma Stock Up 9.7 %
Shares of NVCT traded up $0.72 during trading hours on Wednesday, reaching $8.15. 176,446 shares of the company traded hands, compared to its average volume of 102,861. The business has a fifty day moving average price of $6.81 and a 200-day moving average price of $6.68. Nuvectis Pharma has a 12-month low of $5.85 and a 12-month high of $12.10. The stock has a market capitalization of $152.00 million, a P/E ratio of -6.32 and a beta of 0.41.
Institutional Trading of Nuvectis Pharma
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in Nuvectis Pharma during the second quarter valued at approximately $58,000. Nations Financial Group Inc. IA ADV purchased a new position in shares of Nuvectis Pharma during the 3rd quarter valued at approximately $63,000. Baxter Bros Inc. acquired a new position in shares of Nuvectis Pharma in the 2nd quarter valued at $79,000. GSA Capital Partners LLP boosted its holdings in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock worth $315,000 after buying an additional 1,790 shares in the last quarter. Finally, Iridian Asset Management LLC CT acquired a new stake in Nuvectis Pharma during the third quarter valued at $348,000. Institutional investors and hedge funds own 96.77% of the company's stock.
Nuvectis Pharma Company Profile
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
See Also
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
